HC Wainwright Reaffirms “Buy” Rating for Compass Pathways (NASDAQ:CMPS)

Compass Pathways (NASDAQ:CMPS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Monday, Benzinga reports.

A number of other equities analysts also recently commented on the company. Wall Street Zen upgraded Compass Pathways from a “strong sell” rating to a “sell” rating in a research report on Sunday. Royal Bank Of Canada restated an “outperform” rating on shares of Compass Pathways in a research report on Wednesday. B. Riley Financial lifted their target price on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a report on Tuesday, November 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

Compass Pathways Price Performance

Shares of NASDAQ CMPS opened at $8.61 on Monday. The firm has a 50-day simple moving average of $12.32 and a 200-day simple moving average of $10.41. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways has a 52 week low of $4.88 and a 52 week high of $15.87.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08. On average, equities analysts predict that Compass Pathways will post -0.83 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Candriam S.C.A. lifted its stake in Compass Pathways by 18.6% during the third quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock worth $18,862,000 after purchasing an additional 236,417 shares during the last quarter. Eagle Health Investments LP grew its stake in shares of Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after purchasing an additional 541,039 shares during the last quarter. CenterBook Partners LP increased its holdings in shares of Compass Pathways by 454.1% in the third quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock valued at $8,658,000 after purchasing an additional 570,349 shares during the period. Orbimed Advisors LLC purchased a new stake in shares of Compass Pathways during the first quarter worth approximately $6,363,000. Finally, Affinity Asset Advisors LLC raised its stake in shares of Compass Pathways by 454.2% during the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after purchasing an additional 908,483 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.